Digital biomarkers refer to the quantifiable, physiological, and behavioural data collected and measured by means of digital devices. These devices include sensors, wearables, implantables, and mobile phones. Digital biomarkers offer a patient-centric approach to therapeutics with the attitude that no one device is applicable to all cases. In particular, sensor technology is selected on a case-to-case basis during a data analytics phase where the goal is to extract objective measures reflecting a typical disease manifestation. This information is used to align with targeted concepts of interest and enhance the value of medicine through objective or real-world patient data.
Developing Digital Biomarkers for Rheumatoid Arthritis: a GSK Case Study
While there are some broad cross therapy applications, each disease area has its own unique set of challenges and requirements, resulting in a diversity of applications across the GSK portfolio. The digital biomarkers team at GSK focuses on assessing efficacy, safety, and patient stratification. In his presentation, Valentin Hamy, Data Analytics Leader – Digital Biomarker at GSK focused on efficacy with a case study on rheumatoid arthritis where GSK aim to capture patient function for the generation of patient-centric endpoints.